Form D · Biotechnology
Statera Biopharma, Inc.
Fort Collins, CO · CIK 0001318641
Offering snapshot reported Nov 7, 2022 · SEC filing
- Reported sold
- $577K Offering amount: $765K
- Investors reported
- 12 Form D · investor count
- Minimum accepted
- $50K Reported outside-investor minimum
- First sale
- Nov 1, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Nov 7, 2022 | Initial | $577,000 | No comparison | 12 | SEC filing |
| Jun 4, 2020 | Initial | $1,588,262 | No comparison | 3 | SEC filing |
| Dec 23, 2015 | Initial | $1,140,157 | No comparison | 1 | SEC filing |
| Jul 16, 2015 | Initial | $25,000,000 | No comparison | 1 | SEC filing |
| Jul 3, 2014 | Initial | $3,500,000 | No comparison | 3 | SEC filing |
| Mar 5, 2010 | Initial | $5,000,000 | No comparison | 9 | SEC filing |
| Apr 3, 2009 | Initial | $3,726,557 | No comparison | Not reported | SEC filing |
| Feb 27, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Apr 4, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Mar 14, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Feb 18, 2005 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-463987
Source: Form D, filed Nov 7, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Alexander Andryushechkin | Director |
| James J Antal | Director |
| Julia R. Brown | Director |
| Robert Buckheit | Executive |
| Satish Chandren | Director |
| Paul Di Corleto | Director |
| Anna Evdokimova | Director |
| Ivan Fedyunin | Director |
| Michael Fonstein | Director, Executive |
| Konstantinie Gorshkov | Director |
| Konstantin Gorshkov | Director |
| Andrei Gudkov | Director, Executive |
| Andrei Gudkov, Ph.D., D., Sci. | Executive |
| Michael Kevin Handley | Director, Executive, Promoter |
| Blake Hawley | Director |
| Daniel F. Hoth | Director |
| John Kallassy | Director |
| Bernard Kasten | Director |
| Natalia Khudyk | Director |
| Yakov Kogan | Director, Executive |
| Yulia Lebedina | Director |
| Tatiana Levina | Director |
| C Neil Lyons | Executive |
| C. Neil Lyons | Executive |
| Jack Marhofer | Executive |
| John Marhofer | Executive |
| Richard S Mc Gowan | Director |
| Langdon Miller | Executive |
| Langdon Miller, Md | Executive |
| Daniel Perez | Director |
| Ivan Persiyanov | Director |
| Alexander Polinsky | Director |
| Anthony J Principi | Director |
| Randy S. Saluck | Director |
| Natalia Saraeva | Director |
| Uday Saxena | Director |
| Daniil Talyanskiy | Director |
| Lea Verny | Director |
| Christopher Zosh | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
4333 Corbett Drive Suite 1082
Fort Collins, CO, 80525
Fort Collins, CO, 80525